Recombinant α-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma

M. R. Sertoli, I. Brunetti, A. Ardizzoni, A. Falcone, D. Guarneri, F. Boccardo, G. Martorana, A. Curotto, A. Sicignano, R. Rosso, L. Santi

Research output: Contribution to journalArticle

Abstract

Twenty consecutive metastatic renal cell carcinoma patients were treated with a combination of recombinant α-2a interferon (18 x 106 U three times weekly) and vinblastine (0.1 mg/kg every 3 weeks). Two patients (10% response rate; 95% confidence limits 1.23-31.7%) achieved partial response and 11 (55%) stable disease. Toxicity was significant but always acceptable: most frequently, patients complained of fever and flu-like symptoms (18 of 19 patients), fatigue (18 of 19 patients), worsening in performance status (15 of 19 patients), and anorexia (15 of 19). The combination of recombinant α-2a interferon and vinblastine is active in renal cell carcinoma.

Original languageEnglish
Pages (from-to)43-45
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume12
Issue number1
Publication statusPublished - 1989

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Recombinant α-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Sertoli, M. R., Brunetti, I., Ardizzoni, A., Falcone, A., Guarneri, D., Boccardo, F., Martorana, G., Curotto, A., Sicignano, A., Rosso, R., & Santi, L. (1989). Recombinant α-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 12(1), 43-45.